67. Evaluating Exposure and Risk for Hepatitis C (HCV): Lessons Learned from a Drug Diverter and Serial HCV Infector
Session: Symposium: Preventing Infection in Healthcare Personnel
Thursday, October 3, 2013: 8:30 AM
Room: The Moscone Center: 103 (Gateway Ballroom)
Carlene Muto, MD, MS, FSHEA, Infection Prevention & Hospital Epidemiology, University of Pittsburgh Medical Center, Presbyterian University Hospital, Pittsburgh, PA

Dr. Muto’s primary role is to provide clinical and epidemiologic expertise. She eceived an MS of Epidemiology during her ID training at the University of Virginia and her research interests have focused on reduction/elimination of health-care associated infections (HAIs), with special emphasis on multidrug resistant bacteria such as MRSA and VRE. In 2001, she designed and implemented a “bundle” of organism specific measures that included ADI that have effectively controlled pathogen transmission and resulted in significant MDRO HAI reductions. Similarly, Clostridium difficile HAIs were effectively decreased by applying organism specific interventions resulting in a 75% reduction HA-CDIs. Additionally she headed a central-line associated blood stream infections (CLABSIs) reduction initiative that resulted in >70% CLAB rate reduction now sustained for more than a decade. She has participated in many patient safety committees locally and nationally including chairing the Pittsburgh Regional Health-care Initiative (PRHI) Nosocomial Infection Advisory Committee, serving as a member of the PHC4 HAI Advisory Panel, and a member of Office of Health-care reform Patient Safety Committee. Currently she is a member of the PA Patient Safety Authority Infection Advisory Panel, and a member of SHEA, APIC, IDSA and ASM. Current projects include evaluating risk factors associated with carbapenem resistant enterobactereacea (CRE) colonization and studying the effect of expanded surgical site infection prevention measures.

Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.